Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4 Stomach Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Lymphoma 2 Lung Neoplasms 2 Hematologic Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Recurrent Squamous Cell Lung Carcinoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Muscle Invasive Bladder Cancer 1 Melanoma 1 Glioma 1 FGFR1 Gene Amplification 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

tislelizumab 2 Cystectomy 2 vistusertib 1 toripalimab 1 olaparib 1 liposomal doxorubicin 1 durvalumab 1 disitamab vedotin 1 danvatirsen 1 adavosertib 1 Surgical Procedures, Operative 1 Rutin 1 Radiation 1 RC48 antibody 1 Neoadjuvant Therapy 1 Gemcitabine 1 Cisplatin 1 Chemoradiotherapy 1 AZD4547 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle Invasive Bladder Cancer × AZD4547 × Clear all

NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡